重组CD300c-Ig融合蛋白减轻小鼠胶原诱导性关节炎
该研究在胶原诱导性关节炎(CIA)小鼠模型中评估重组CD300c-Ig融合蛋白的预防和治疗作用。结果显示CD300c-Ig可降低CIA发病率及临床和病理评分,改善已建立的CIA,并抑制T细胞增殖活化、Th1/Th17细胞因子产生及CII自身抗体生成,体外亦抑制RA患者T细胞增殖活化。
要点
- CD300c-Ig在预防模型中降低CIA发病率及临床和病理评分。
- CD300c-Ig在治疗模型中改善已建立的CIA。
- CD300c-Ig抑制T细胞增殖活化、Th1/Th17细胞因子及CII自身抗体。
核心结论
- CD300c-Ig蛋白有潜力用于治疗RA患者。
研究设计与样本
- 小鼠经CII诱导CIA,在CIA症状出现前或后注射CD300c-Ig或对照Ig蛋白。
- 检测CIA临床和病理评分、促炎细胞因子表达、CD4 T细胞和调节性T细胞比例及活化、CII特异性T细胞增殖和细胞因子产生、CII特异性自身抗体产生。
- 体外检测CD300c-Ig对RA患者T细胞增殖和活化的影响。
主要发现
- 预防模型中CD300c-Ig显著降低CIA发病率,并降低临床和病理关节炎评分。
- 治疗模型中CD300c-Ig改善已建立的CIA。
- CD300c-Ig的有益效应与脾脏T细胞扩增和活化减少及关节促炎细胞因子表达降低相关。
- CD300c-Ig抑制CII特异性T细胞增殖及Th1和Th17细胞因子产生。
- CD300c-Ig治疗降低血清中CII自身抗体产生,并体外抑制RA患者T细胞增殖和活化。
临床怎么用
- CD300c-Ig通过抑制T细胞活化、Th1/Th17反应及自身抗体产生减轻CIA,提示靶向CD300c可能为RA治疗提供新思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RA is a chronic autoimmune disease characterized by joint inflammation and tissue destruction. Immune responses mediated by T cells and autoantibodies are known to play critical roles in RA. Collagen type II (CII)-induced arthritis (CIA) is a commonly used animal model of human RA. We have previously reported the identification of a new T cell inhibitory molecule CD300c. Here we investigate the ability of recombinant CD300c-IgG2a Fc (CD300c-Ig) fusion protein to prevent and treat CIA. METHODS: Mice were induced to develop CIA by CII and injected with CD300c-Ig or control Ig protein before or after CIA symptoms occur. The mice were examined for CIA clinical and pathological scores, and analysed for the expression of proinflammatory cytokines, the percentage and activation of CD4 T cells and regulatory T cells, CII-specific T cell proliferation and cytokine production, and CII-specific autoantibody production. RESULTS: In a prevention model, CD300c-Ig significantly decreases CIA incidence, and reduces clinical and pathological arthritis scores. In the treatment model, CD300c-Ig ameliorates established CIA. The beneficial effects of CD300c-Ig are related to decreased expansion and activation of T cells in the spleen and reduced expression of proinflammatory cytokines in the joints. CD300c-Ig also inhibits CII-specific T cell proliferation and Th1 and Th17 cytokine production. In addition, CD300c-Ig treatment reduced the production of CII autoantibodies in the serum. Furthermore, CD300c-Ig inhibits the proliferation and activation of T cells from RA patients in vitro. CONCLUSION: CD300c-Ig protein has the potential to be used in the treatment of patients with RA.
引用
- Liu H, Zhao J, Su M, et al. Recombinant CD300c-Ig fusion protein attenuates collagen-induced arthritis in mice. Rheumatology (Oxford). 2022. PMID: 34021311. doi:10.1093/rheumatology/keab450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。